TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2885505
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Sb/kg per day for twenty days
Study: 27457369
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT, 0.3 W, 40 s, 4 J/cm²)
Study: 22000279
Drug: Istradefylline 10
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Istradefylline 10 mg/day
Study: 18685349
Drug: Low-dose regular
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose regular opioids (especially sustained-release preparations)
Study: 18685349
Drug: Other medications
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medications (benzodiazepines, nebulised frusemide, selective serotonin reuptake inhibitors)
Study: 11844656
Drug: Cholestin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestin (1.2 g twice daily for 8 weeks)
Study: 11844656
Drug: Cholestin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestin (1.2 g twice daily for 2 weeks)
Study: 7480980
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rhDNase twice daily for 6 months followed by a 2-week wash-out period, then rhDNase once daily for 18 months
Study: 1673816
Drug: Ephedrine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.07 mg kg‐1
Study: 1673816
Drug: Etilefrine 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine 0.03 mg kg‐1
Study: 7125090
Drug: Soludactone: 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soludactone: 300 mg daily for one week, followed by aldactone orally
Study: 22906319
Drug: Graded-exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded-exercise therapy (GET)
Study: 17299581
Drug: Phaseolus vulgaris
Normalized name: PHASEOLUS VULGARIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phaseolus vulgaris extract (445 mg) taken one tablet per day for 30 days before a carbohydrate-rich meal
Study: 17299581
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken one tablet per day for 30 days before a carbohydrate-rich meal
Study: 11606175
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1250 mg) and Vitamin E (680 IU) per day
Study: 9540877
Drug: Omeprazole/amoxicillin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole/amoxicillin for 2 weeks
Study: 20557237
Drug: Azithromycin-artesunate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin-artesunate (30 mg/kg per day of azithromycin plus 4 mg/kg per day of artesunate) once daily for 3 days
Study: 20557237
Drug: Control: Artemether
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Artemether (80 mg) plus Lumefantrine (960 mg) twice daily for 3 days
Study: 18534016
Drug: ACZ885 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACZ885 10 mg/kg
Study: 18991519
Drug: Touch treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Touch treatment (twice-weekly for 8 weeks)
Study: 18991519
Drug: Distant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distant therapy (twice-weekly for 8 weeks)
Study: 18991519
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control (twice-weekly for 8 weeks)
Study: 15149781
Drug: Hexavalent DTPa‐HBV‐IPV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent DTPa‐HBV‐IPV/Hib vaccine (Infanrix hexa)
Study: 15149781
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTPa‐IPV/Hib and HBV vaccines
Study: 11054323
Drug: Tamoxifen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (oral administration)
Study: 1378786
Drug: Intravenous gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gallopamil 0.03 mg/kg
Study: 29540123
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate combined with oral nimodipine
Study: 15292287
Drug: Additional morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional morning dose of hydrocortisone
Study: 8164045
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg isotretinoin daily for 6 months
Study: 29127533
Drug: Ontuxizumab 2
Normalized name: Ontuxizumab
DrugBank: Ontuxizumab (DB16270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontuxizumab 2 mg/kg
Study: 29127533
Drug: Ontuxizumab 4
Normalized name: Ontuxizumab
DrugBank: Ontuxizumab (DB16270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontuxizumab 4 mg/kg
Study: 29127533
Drug: Ontuxizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontuxizumab (both doses)
Study: 12442345
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 or 10 mg)
Study: 9989712
Drug: Hirudin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (0.4 mg/kg bolus then 0.15 mg kg(‐1) h(‐1) infusion; n=5083)
Study: 31715077
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily (n = 30)
Study: 3717693
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of 1 unit of blood @ 5 ml/min
Study: 3717693
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of 2 units of blood @ 10 ml/min
Study: 3717693
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of 2 units of blood @ 5 ml/min
Study: 3717693
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of 1 unit of blood @ 10 ml/min
Study: 28918703
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (MMH, PPH, PPH+sMMH)
Study: 23231499
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg of misoprostol orally
Study: 21796123
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (standard-dose candesartan 8 mg/day + controlled-release nifedipine 20 mg/day)
Study: 21796123
Drug: Up-titrated monotherapy
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titrated monotherapy (candesartan 12 mg/day)
Study: 11025708
Drug: Bicalutamide monotherapy
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide monotherapy (150 mg daily)
Study: 11025708
Drug: Castration (orchiectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castration (orchiectomy or 3.6 mg goserelin acetate every 28 days)
Study: 9195140
Drug: Perceptual assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceptual assessment and treatment provided in a stroke unit
Study: 8257455
Drug: gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil 1200 mg daily
Study: 28560853
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed plus carboplatin)
Study: 8469323
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) 3,600 mg/d
Study: 8469323
Drug: Valproate (VPA)
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate (VPA) 15 mg/kg/d
Study: 17710973
Drug: Hib‐TT mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib‐TT mixed with GSK's DTPw vaccine (Tritanrix; group 3)
Study: 15359983
Drug: Clearance after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearance after cimetidine administration
Study: 12119060
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPIs) - omeprazole, rabeprazole, pantoprazole, or lansoprazole
Study: 12119060
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPIs) - newer PPIs (rabeprazole, pantoprazole, lansoprazole)
Study: 12119060
Drug: Histamine 2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine 2-receptor antagonist (ranitidine)
Study: 1486186
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily at night
Study: 114055
Drug: Montanoa tomentosa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montanoa tomentosa extracts (Zoapatle) administered orally at a daily dose of 1.0 to 1.4 gm-equivalent of dry leaves per kilogram of body weight for two days
Study: 26180051
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation, dosage not specified, duration not specified.
Study: 19407947
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (Zhao's Weitiao No. 3, 40 mL twice a day for 30 days, 6 cycles)
Study: 19407947
Drug: Chemotherapy (OLF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (OLF protocol: L-OHP+LV+5-FU for 4-6 cycles)
Study: 18162018
Drug: Ziprasidone 10-20
Normalized name: ziprasidone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 10-20 mg
Study: 18162018
Drug: Aripiprazole 9.75
Normalized name: ARIPIPRAZOLE 9.75MG/1.3ML (7.5MG/ML) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 9.75 mg
Study: 15313741
Drug: 13-hour curriculum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-hour curriculum in which residents practiced teaching and received feedback during 1-hour small-group sessions taught twice monthly for 6 months
Study: 11207174
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (50 mg/kg once daily) for 10 days
Study: 11207174
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (50 mg/kg once daily) for 3 days
Study: 23239683
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (3 g daily for 60 days)
Study: 9062860
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (negative control in experiments 2 and 3)
Study: 8072836
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose RSV immunoglobulin (RSVIG)
Study: 2553511
Drug: Bulk laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk laxative (plantago rind and sorbitol)
Study: 26931362
Drug: Proactive outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive outreach intervention (tailored mailings and telephone calls) with free cessation treatment (nicotine replacement therapy and intensive telephone counselling)
Study: 31483549
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (access to a primary care physician, insurance coverage of FDA-approved smoking cessation medications, and the state's telephone quitline)
Study: 19635962
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g three times a day
Study: 19635962
Drug: Ceftazidime 6
Normalized name: ceftazidime 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 6 g per day continuously
Study: 11380911
Drug: Additional IVIG
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional IVIG treatment (1 g/kg)
Study: 18540358
Drug: Steroid pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pulse therapy
Study: 8466726
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg twice daily
Study: 7043448
Drug: Combined clomiphene-parlodel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined clomiphene-parlodel treatment
Study: 30381412
Drug: Patiromer 8.4
Normalized name: patiromer 8.4 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 8.4 g once daily without/with food for 4 weeks
Study: 23640923
Drug: Lcn2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lcn2 treatment in adipocytes
Study: 21209304
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment plus religious and spiritual assessment
Study: 15569835
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg and losartan 100 mg
Study: 15717138
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg
Study: 11224005
Drug: Fasting glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose, fasting insulin, insulin 120 min after glucose ingestion
Study: 9846679
Drug: GnRH-agonist down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-agonist down regulation for 25-40 days (Group B)
Study: 7855098
Drug: Tea consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea consumption (8 g of instant tea) during supplementation periods in Study A
Study: 7855098
Drug: Tea consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea consumption (8 g of instant tea) during supplementation periods in Study B
Study: 7855098
Drug: No tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tea dietary treatments in Study A
Study: 7855098
Drug: No tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tea dietary treatments in Study B
Study: 2239725
Drug: Full-dose labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose labetalol
Study: 2239725
Drug: Half-dose labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose labetalol
Study: 2239725
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with half-dose labetalol
Study: 2239725
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with full-dose labetalol
Study: 28667579
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 3000 mg plus wheat germ oil (WGO) 300 mg
Study: 26126970
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (WP) for 12 treatments
Study: 23444963
Drug: High kimchi
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High kimchi intake (210 g/day)
Study: 23444963
Drug: Low kimchi
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low kimchi intake (15 g/day)
Study: 19173710
Drug: Alanine-glutamine infusion
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alanine-glutamine infusion at a rate of 0.025 g/(kg body weight x hour) for 10 hours
Study: 17365735
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 21 mg/day
Study: 17365735
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 42 mg/day
Study: 9006598
Drug: Nurse-initiated daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-initiated daily phone calls program
Study: 8252685
Drug: Contrast agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agents (general)
Study: 3520469
Drug: Amoxicillin-clavulanate potassium
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate potassium (Augmentin)
Study: 8053613
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg/d)
Study: 27936344
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of HZ/su vaccine
Study: 22012543
Drug: Magnesium Group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium Group (10% magnesium sulphate 2 mL)
Study: 22012543
Drug: Saline Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Group (normal saline 2 mL)
Study: 20889389
Drug: Study Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Care (SC): reassurance and avoidance of passive treatments, acetaminophen, 4 weeks of lumbar chiropractic spinal manipulative therapy (CSMT), and return to work within 8 weeks
Study: 9650682
Drug: ACTH therapy
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH therapy (0.025 mg/kg/day, administered intramuscularly for 6 weeks, total dosage = 0.625 mg/kg)
Study: 31015261
Drug: IL‐1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1 receptor antagonist (study B)
Study: 21652615
Drug: i-gel™ with
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel™ with Magill PVC tube
Study: 17547798
Drug: Dixson 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixson 0.75 kcal/ml (TPF-DM)
Study: 17547798
Drug: Nutrition MF
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition MF 0.75 kcal/ml (standard formula)
Study: 15337732
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 1 month followed by 80 mg/d thereafter
Study: 21477202
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d
Study: 25809332
Drug: Pectin 24
Normalized name: opium/kaolin/pectin 24 mg ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin 24 g powder/d (n=46)
Study: 22303576
Drug: Dietetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic treatment for childhood obesity (8 sessions of an 8-hour family-centred group treatment programme based on behavioural change techniques)
Study: 9327371
Drug: Standard plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plus supplemental vitamin A (2.6 mumol/l [2500 IU] orally each day)
Study: 27282488
Drug: Dithiothreitol (DTT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithiothreitol (DTT) treatment
Study: 27282488
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution treatment
Study: 22717217
Drug: Orlistat 60
Normalized name: orlistat 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 60 mg (three capsules daily with meals)
Study: 20524987
Drug: TZP-101 80
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZP-101 80 μg kg(‐1)
Study: 18669453
Drug: Chemotherapy (fluorouracil/leucovorin)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (fluorouracil/leucovorin) with radiotherapy (50 Gy) and adjuvant for 16 weeks after surgery (CRT group, n = 98)
Study: 12892687
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol 1 mg/day
Study: 6518461
Drug: Bolar quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolar quinidine gluconate tablets (Bolar Pharmaceutical Company)
Study: 29526860
Drug: expanded Constraint‐Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: expanded Constraint‐Induced Movement Therapy (eCIMT)
Study: 23359966
Drug: External application
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External application of Compound Tripterygium wilfordii (CTW)
Study: 12549945
Drug: On-site antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site antifungal susceptibility testing (AST)
Study: 25376617
Drug: IBI‐20089 (6.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI‐20089 (6.9 mg or 13.8 mg TA) followed by ranibizumab (0.5 mg)
Study: 25376617
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IBI‐20089 and ranibizumab)
Study: 15095932
Drug: Nonenteric-coated aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonenteric-coated aspirin
Study: 15095932
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa receptor inhibitors, unfractionated heparin (UFH), and clopidogrel (Plavix)
Study: 15095932
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa receptor inhibitors (tirofiban, eptifibatide, abciximab)
Study: 15095932
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive or early conservative therapy
Study: 9768766
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 microg/kg (Group G)
Study: 30661477
Drug: Roux-en-Y Gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y Gastric Bypass (RYGB) combined with medical therapy
Study: 21868796
Drug: Ice therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice therapy, NSAIDs, stretching and strengthening program
Study: 21868796
Drug: Ice therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice therapy, NSAIDs, stretching and strengthening program, reinforced by acupuncture treatment
Study: 18715283
Drug: NTX 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX 0.125 mg
Study: 18715283
Drug: NTX 0.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX 0.250 mg
Study: 17917992
Drug: 8 hours
Normalized name: Thermacare Muscle/Joint 8 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 hours of training emphasizing interviewing behaviours in the diagnosis and treatment of depression and GAD
Study: 9552221
Drug: i.v. methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. methylprednisolone (40 mg/day) and oral placebo (t.i.d.)